Please login to the form below

Not currently logged in
Email:
Password:

Cannabis medicines for Alzheimer's disease

Patients suffering from Alzheimer's disease could be treated with cannabis according to new research data

Patients suffering from Alzheimer's disease could be treated with cannabis according to new research data.

During a symposium at the Royal Pharmaceutical Society of Great Britain (RPSGB) on March 10, Professor Raphael Mechoulam of the Hebrew University of Jerusalem presented findings that indicated the potential benefits of cannabis-derived medicines.

Research, which is still in early stages, shows that the chemicals present in cannabis can slow down memory loss, the most prevalent feature of Alzheimer's disease.

Professor Tony Moffat, chairperson of the RPSGB symposium, said: "Although recent press coverage has focused on the abuses associated with the plant, cannabis-derived medications may offer novel opportunities in drug discovery.

"There is currently considerable interest in the medical benefits of cannabis and related compounds for a range of conditions including arthritis, multiple sclerosis and neurological pain."

Alzheimer's disease is the most common form of dementia and affects 417,000 people in the UK and 24.3mn across the world.

The trails conducted so far have only shown the effect of cannabis medicines on mice, but the next step for researchers will be to initiate human patient studies.

10th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics